News

EMA recommends granting marketing authorisation approval for Nezglyal

Jul 27, 2026 | News, Regulatory

The treatment is for cerebral adrenoleukodystrophy, a rare neurodegenerative disease

MAD World Summit 2026: where the future of workplace well-being takes centre stage

Jul 27, 2026 | News, Marketing

The event takes place on Thursday 26 November 2026 in the heart of London at Convene, 155 Bishopsgate

AstraZeneca’s Trixeo recommended by CHMP for approval in EU for asthma

Jul 24, 2026 | News, Regulatory

Asthma affects over 360 million people worldwide, including over 40 million people in Europe

Pfizer’s Talzenna plus Xtandi gets FDA Priority Review for metastatic prostate cancer

Jul 23, 2026 | News, Research

The phase 3 trial showed greater than 50% improvement in radiographic progression-free survival

Takeda’s zasocitinib shows high rates of skin clearance in phase 3 psoriasis studies

Jul 22, 2026 | News, Research

Globally, an estimated 64 million people have psoriasis, with about 80-90% of those having plaque psoriasis

Almirall’s paediatric registration of Ebglyss for atopic dermatitis gets EMA acceptance

Jul 21, 2026 | News, Regulatory

Atopic dermatitis affects a significant number of children and adolescents and often peaks in childhood

Lilly to acquire AtaiBeckley in deal worth $2.8bn

Jul 20, 2026 | News, Sales

The acquisition will advance therapies for treatment-resistant depression and other mental health conditions

Veradermics’ oral treatment for female pattern hair loss delivers positive study results

Jul 16, 2026 | News, Research

Pattern hair loss affects around 30 million women and 50 million men in the US

Biogen and Eisai’s Leqembi study shows nearly 83% of early Alzheimer’s patients remained stable or improved

Jul 15, 2026 | News, Research

The real-world findings support the long-term benefits of continuous treatment

Alzheimer’s groups call for urgent global focus on women’s brain health

Jul 15, 2026 | News, Healthcare

New op-ed published by leaders from the Women’s Alzheimer’s Movement at Cleveland Clinic, Alzheimer’s Research UK and the Alzheimer’s Association

AstraZeneca agrees on $1.5bn deal with Dizal Pharmaceutical

Jul 14, 2026 | News, Sales

The company will gain a novel oral treatment for lung cancer

Bristol Myers Squibb’s New Drug Application for mezigdomide accepted by FDA

Jul 13, 2026 | News, Regulatory

Mezigdomide improves progression-free survival in patients with relapsed or refractory multiple myeloma

EMA recommends granting marketing authorisation approval for Nezglyal

MAD World Summit 2026: where the future of workplace well-being takes centre stage

AstraZeneca’s Trixeo recommended by CHMP for approval in EU for asthma

Pfizer’s Talzenna plus Xtandi gets FDA Priority Review for metastatic prostate cancer

Takeda’s zasocitinib shows high rates of skin clearance in phase 3 psoriasis studies

Almirall’s paediatric registration of Ebglyss for atopic dermatitis gets EMA acceptance

Lilly to acquire AtaiBeckley in deal worth $2.8bn

Veradermics’ oral treatment for female pattern hair loss delivers positive study results

Biogen and Eisai’s Leqembi study shows nearly 83% of early Alzheimer’s patients remained stable or improved

Alzheimer’s groups call for urgent global focus on women’s brain health

AstraZeneca agrees on $1.5bn deal with Dizal Pharmaceutical

Bristol Myers Squibb’s New Drug Application for mezigdomide accepted by FDA

Latest content

Latest intelligence

Quick links